Looking for a Wegovy Alternative?
Quick answer
Wegovy is Novo Nordisk's brand-name semaglutide for weight management. It costs roughly $1,350/mo retail. LYV prescribes compounded tirzepatide instead -- a different (and clinically superior) compound. In the SURMOUNT-5 trial, tirzepatide produced 47% more weight loss than semaglutide head-to-head. LYV's compounded tirzepatide starts at $197/mo.
What Wegovy offers
Wegovy was a breakthrough. It normalized GLP-1 therapy for weight loss and brought the conversation into the mainstream. Semaglutide is a well-studied compound with strong evidence -- 14.9% body weight loss in the STEP 1 trial. Wegovy also has the SELECT trial showing a 20% reduction in major cardiovascular events, which is significant data that no other weight loss medication has matched. Novo Nordisk has invested heavily in manufacturing capacity and patient support programs.
Wegovy vs LYV
| Wegovy | LYV | |
|---|---|---|
| Active compound | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Avg weight loss | 14.9% (STEP 1) / 13.7% (SURMOUNT-5) | 22.5% (SURMOUNT-1) / 20.2% (SURMOUNT-5) |
| Monthly cost | ~$1,350/mo retail | From $197/mo (compounded) |
| Cardiovascular data | SELECT trial: 20% MACE reduction | CV outcome trials ongoing |
| FDA indication | Chronic weight management | Compounded (tirzepatide molecule) |
| Dosing | Once weekly injection | Once weekly injection |
| Manufacturer | Novo Nordisk | Licensed US compounding pharmacy |
Where LYV differs
- •LYV prescribes tirzepatide, not semaglutide. The SURMOUNT-5 head-to-head trial showed tirzepatide produced 47% more weight loss. If maximum fat loss is your goal, the data favors tirzepatide.
- •Cost: $197/mo for compounded tirzepatide vs $1,350/mo for brand-name Wegovy. Even comparing to compounded semaglutide from other providers, tirzepatide's superior efficacy means you get more result per dollar.
- •Tirzepatide's dual mechanism (GIP + GLP-1) targets insulin sensitivity in addition to appetite -- relevant if you have metabolic syndrome or pre-diabetes.
- •Wegovy has stronger cardiovascular outcome data (SELECT trial). If you have specific cardiovascular risk factors, discuss this with your provider. For pure weight loss, tirzepatide is the stronger compound.
Frequently asked questions
Is tirzepatide really better than semaglutide for weight loss?
In the SURMOUNT-5 head-to-head trial, yes. Tirzepatide produced 20.2% body weight loss vs 13.7% for semaglutide over 72 weeks. That is 47% more weight loss from tirzepatide. This is published data from the New England Journal of Medicine, not marketing.
What about Wegovy's cardiovascular benefits?
The SELECT trial showed semaglutide reduced major cardiovascular events by 20%. This is meaningful data. Tirzepatide cardiovascular outcome trials are ongoing. If you have significant cardiovascular risk, discuss this specific consideration with your prescribing provider.
Why does LYV not offer semaglutide?
We prescribe the compound with the strongest evidence for each goal. For weight loss, tirzepatide outperforms semaglutide in every measure. We would rather give you the most effective option than offer multiple choices that include a less effective one.
Can I switch from Wegovy to tirzepatide?
Yes. Your LYV provider determines the appropriate tirzepatide starting dose based on your current semaglutide dose. There is typically no washout period. Many patients transition smoothly and notice additional appetite suppression and weight loss after switching.
Is $197/mo the real price?
Yes. That is the all-in monthly price including provider consultation, tirzepatide prescription, and shipping. No hidden fees, no separate charge for the visit, no surprise costs after month one.
See how LYV matches your goals
Take a 2-minute quiz. Get a personalized protocol.